|
Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects Clinical research trials and Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects. Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects clinical trial. Human subjects often receive the most effective healthcare possible for their Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects  Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
For Condition: HIV Infections
Status: Recruiting
Sponsor(s): Sponsor Name Pending ,
Synopsis: This is a 48-week study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of an investigational regimen including FDA approved HIV drugs in HIV-infected pediatric subjects, ages 4 weeks to < 2 years old.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety Study
Minimum Age/Maximum Age: /2 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Male or females 4 weeks to < 2 years of age - Parent or legal guardian has the ability to understand and provide written informed consent. - Screening plasma HIV-1 RNA > or = 400 copies/mL. - Must be able to construct an active 2 NRTI (nucleoside reverse transcriptase inhibitor) backbone regimen. Exclusion Criteria (patients cannot meet the following criteria in order to be considered eligible for this study): - Prior history of having received the drug AGENERASE. - Non-nucleoside reverse transcriptase inhibitor (NNRTI) therapy within 14 days prior to study Day 1 or anticipated need for concurrent NNRTI therapy during the study period. - PI (protease inhibitor) therapy within 5 days prior to study drug administration - Have not had an AIDS defining illness (acute CDC Category C event) within 28 days of screen. - Other inclusion or exclusion criteria to be determined by the physician.
Total Enrollment:
Location and Contact Information:
Study Site *Not yet recruiting*
Jacksonville, Florida, 32209
United States
Not yet recruiting Study Coordinator 904-244-5331
Study Site *Not yet recruiting*
Bronx, New York, 10461
United States
Not yet recruiting Study Coordinator 718-918-4516
Study Site *Not yet recruiting*
New York City, New York, 10016
United States
Not yet recruiting Study Coordinator 212-263-5680
Study Site *Recruiting*
Mexico Distrito Federal, , CP 06720
Mexico
Recruiting Study Coordinator 011-52-55-5588-7781
Study Site *Not yet recruiting*
Durham, North Carolina, 27705
United States
Not yet recruiting Study Coordinator 919-416-9268
Study Site *Not yet recruiting*
Mexico, , 06720
Mexico
Not yet recruiting Study Coordinator 011-52-55-5623-2668
Study Site *Not yet recruiting*
Syracuse, New York, 13210
United States
Not yet recruiting Study Coordinator 315-464-6331
Study Site *Not yet recruiting*
San Juan, , 00936
Puerto Rico
Not yet recruiting Study Coordinator 787-759-9595
Study Site *Not yet recruiting*
Lisboa, , 1649-035
Portugal
Not yet recruiting Study Coordinator 011-35121780522
Study Site *Not yet recruiting*
Porto, , 4200-319
Portugal
Not yet recruiting Study Coordinator 011-351 22 550 1
Study Site *Not yet recruiting*
Panama, , 5-4807
Panama
Not yet recruiting Study Coordinator 011-504-222-1550
Study Site *Not yet recruiting*
Amadora, , 2700-276
Portugal
Not yet recruiting Study Coordinator 011-351 214348299
Study Site *Not yet recruiting*
Buenos Aires, , 1644
Argentina
Not yet recruiting Study Coordinator 011-54-11-4308-4300
Additional Information:
Study ID Numbers: APV20002;
Study Start Date:
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00071760
Other Hiv Infections Studies:
1. A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals
2. A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection
3. A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir
4. Kidney Transplants in People with HIV Infection
5. Treatment with Combinations of Several Antiviral Drugs in Infants and Young Children with HIV Infection
Related Studies:
Other HIV Infections Clinical Trials
Other Clinical Trials
Other Mexico Distrito Federal Clinical Trials
Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
|
|
|
|
|
|
|
|
